Update on COVID Vaccines timelines and clinical data available (only late stage vaccines)

1. Company Candidate Doses Available Clinical Data Next Steps Global Supply and Other Information
BNT162b2
synthetic
mRNA
2
Preliminary Ph3 results anticipated
3rd week of Nov. Phase 1/2 data
published Aug 12
If positive Ph3 results, companies
would submit a request for
Emergency Use (or Expanded
Access) immediately after and if
granted, the rollout of the vaccine
would start soon (first in
prioritized populations).
Pfizer announced ability to supply up to 100 million doses
globally by the end of 2020 and 1,300 million by end of 2021.
One of the challenges facing this vaccine is distribution as it
needs to be stored below -70℃. This increases complexity and
cost.
AZD1222
Chimpanzee
Adeno vector
2
Preliminary Ph3 results anticipated
end-2020. Phase 1/2 data published
Aug 15
UK will receive 4 million doses in 2020 instead of the 100
million previously agree due to manufacturing delays
mRNA-1273
synthetic
mRNA
2
Preliminary Ph3 results anticipated
mid-Nov to early-2021. Ph1 data
published Sep 29
The company expects to be able to produce 20 million doses
by the end of the year, and between 500 million and 1 billion
in 2021
NVX-
COV2373
glycoprotein
nanopartical
2
Company targets to have preliminary
Ph3 results in Dec. Ph1/2 data
published Sep 2
Full enrollment of 15,000 participants to be completed end
Nov.
JNJ-78436735
Ad26 vector
2 Preclinical data published Sep 3 Clinical data still to be published
Agreement with European Commission to supply 200 million
doses and potential 200 million more. Plans to allocate up to
500 million doses for Low- and Middle-Income Countries
COVID Vaccines Timelines (1/2)
Updated 7 November 2020. Own elaboration by Ana Cespedes.

2. Company Candidate Doses Available Clinical Data Next Steps Global Supply and Other Information
BBIBP-CorV x
2
Whole virus
inactivated
2
Not disclosed when Ph2/3 results
would be available. Ph1/2 data
published Aug 13
Despite not having Ph3 results,
Emergency Use Authorization has
been granted in China for high-
risk groups (Aug xx), UAE (Sep 14)
and Bahrain (frontline workers,
Nov 3)
Ph3 ongoing in 10 countries. According to Sinopharm, as of
Oct 15, 481,613 people had taken the vaccine and additional
93,653 had applied to be inoculated.
Government of China has declared that they will make COVID-
19 vaccines a global public good when available, to increase
vaccine accessibility and affordability in developing countries,
including African countries.
Coronavac
Whole virus
inactivated
2
It hasn’t been disclosed when Ph3
results would be available. Ph1/2
results published Sep 23
Despite not having Ph3 results
available, it’s available to general
population in China
Treatment cost in China: 2,000 rmb ($300). Sinovac has
promised to supply 40 million CoronaVac doses to Indonesia
by March 2021. Brazil has also agreed to buy 46 million doses
of CoronaVac
Ad5-nCoV
Non-
replicating
Ad5-vectored
2
It hasn’t been disclosed when Ph3
results would be available
Ph1/2 results published Aug 15
Despite not having Ph3 results
available, China granted an
Emergency Use Authorization (for
military, June 29)
Ph3 trials ongoing globally, including Pakistan and Mexico,
(10,000-15,000 volunteers)
Sputnik V
rAd26 and
rAd5 vector-
based prime-
boost
2
It hasn’t been disclosed when Ph3
results would be available. Ph1/2
data published Sep 26
Despite not having Ph3 results
available, Russia announced its
approval on Aug 11
1.5 million doses ordered by Israel. However, manufacturers
have recently announced that they expect hundreds of
thousands instead of the promised tens of millions of vaccine
doses by year-end
COVID Vaccines Timelines (2/2)
Updated 7 November 2020. Own elaboration by Ana Cespedes.